- Home
- EWCZ vs DSGN Comparison
EWCZ vs DSGN Comparison
Compare EWCZ & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EWCZ
- DSGN
- Stock Information
- Founded
- EWCZ 2004
- DSGN 2017
- Country
- EWCZ United States
- DSGN United States
- Employees
- EWCZ N/A
- DSGN N/A
- Industry
- EWCZ Package Goods/Cosmetics
- DSGN Biotechnology: Pharmaceutical Preparations
- Sector
- EWCZ Consumer Discretionary
- DSGN Health Care
- Exchange
- EWCZ Nasdaq
- DSGN Nasdaq
- Market Cap
- EWCZ 239.2M
- DSGN 208.9M
- IPO Year
- EWCZ 2021
- DSGN 2021
- Fundamental
- Price
- EWCZ $4.22
- DSGN $3.82
- Analyst Decision
- EWCZ Buy
- DSGN Hold
- Analyst Count
- EWCZ 7
- DSGN 1
- Target Price
- EWCZ $5.86
- DSGN $4.00
- AVG Volume (30 Days)
- EWCZ 374.4K
- DSGN 95.8K
- Earning Date
- EWCZ 08-13-2025
- DSGN 08-12-2025
- Dividend Yield
- EWCZ N/A
- DSGN N/A
- EPS Growth
- EWCZ N/A
- DSGN N/A
- EPS
- EWCZ 0.21
- DSGN N/A
- Revenue
- EWCZ $216,469,000.00
- DSGN N/A
- Revenue This Year
- EWCZ N/A
- DSGN N/A
- Revenue Next Year
- EWCZ $2.17
- DSGN N/A
- P/E Ratio
- EWCZ $20.54
- DSGN N/A
- Revenue Growth
- EWCZ N/A
- DSGN N/A
- 52 Week Low
- EWCZ $2.72
- DSGN $2.60
- 52 Week High
- EWCZ $9.45
- DSGN $7.77
- Technical
- Relative Strength Index (RSI)
- EWCZ 26.95
- DSGN 45.61
- Support Level
- EWCZ $4.56
- DSGN $3.76
- Resistance Level
- EWCZ $5.16
- DSGN $4.19
- Average True Range (ATR)
- EWCZ 0.20
- DSGN 0.22
- MACD
- EWCZ -0.07
- DSGN -0.03
- Stochastic Oscillator
- EWCZ 1.44
- DSGN 8.82
About EWCZ European Wax Center Inc.
European Wax Center Inc is a franchisor and operator of OOH waxing services. Its product sales consist of revenue earned from sales of proprietary wax. Its services include Brazilian Waxing, Brow Waxing, Body Waxing, Facial Waxing, All Waxing Services, Eyebrow Tinting, Laser Hair Removal, Men's Waxing Services and others.
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.